[Targeted radionuclide therapy for castration-resistant prostate cancer]

Katsumasa Nakamura, Ohga Saiji, Tomonari Sasaki, Shingo Baba, Hiroshi Honda

Research output: Contribution to journalReview article

Abstract

Although patients with castration-resistant prostate cancer frequently have metastases to the bone, they have a relatively favorable prognosis. Therefore, it is important to keep or improve the level of patient's quality of life. The use of strontium-89 for the management of the pain from bone metastasis was approved in 2007 in Japan. A new bone-targeting radiopharmaceuticals using radium-223 is also promising, because a randomized trial showed an overall survival advantage of radium-223 in prostate patients with bone metastases. In this review, we summarize the role of targeted radionuclide therapy for castration-resistant prostate cancer, focusing on strontium-89 and radium-223.

Original languageEnglish
Pages (from-to)2181-2185
Number of pages5
JournalNihon rinsho. Japanese journal of clinical medicine
Volume72
Issue number12
Publication statusPublished - Dec 1 2014

Fingerprint

Castration
Radioisotopes
Radium
Prostatic Neoplasms
Bone and Bones
Strontium
Neoplasm Metastasis
Radiopharmaceuticals
Pain Management
Therapeutics
Prostate
Japan
Quality of Life
Survival

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

[Targeted radionuclide therapy for castration-resistant prostate cancer]. / Nakamura, Katsumasa; Saiji, Ohga; Sasaki, Tomonari; Baba, Shingo; Honda, Hiroshi.

In: Nihon rinsho. Japanese journal of clinical medicine, Vol. 72, No. 12, 01.12.2014, p. 2181-2185.

Research output: Contribution to journalReview article

@article{789ca15304f94ecf95a68294dbc52ed4,
title = "[Targeted radionuclide therapy for castration-resistant prostate cancer]",
abstract = "Although patients with castration-resistant prostate cancer frequently have metastases to the bone, they have a relatively favorable prognosis. Therefore, it is important to keep or improve the level of patient's quality of life. The use of strontium-89 for the management of the pain from bone metastasis was approved in 2007 in Japan. A new bone-targeting radiopharmaceuticals using radium-223 is also promising, because a randomized trial showed an overall survival advantage of radium-223 in prostate patients with bone metastases. In this review, we summarize the role of targeted radionuclide therapy for castration-resistant prostate cancer, focusing on strontium-89 and radium-223.",
author = "Katsumasa Nakamura and Ohga Saiji and Tomonari Sasaki and Shingo Baba and Hiroshi Honda",
year = "2014",
month = "12",
day = "1",
language = "English",
volume = "72",
pages = "2181--2185",
journal = "Astrophysical Journal",
issn = "0004-637X",
publisher = "IOP Publishing Ltd.",
number = "12",

}

TY - JOUR

T1 - [Targeted radionuclide therapy for castration-resistant prostate cancer]

AU - Nakamura, Katsumasa

AU - Saiji, Ohga

AU - Sasaki, Tomonari

AU - Baba, Shingo

AU - Honda, Hiroshi

PY - 2014/12/1

Y1 - 2014/12/1

N2 - Although patients with castration-resistant prostate cancer frequently have metastases to the bone, they have a relatively favorable prognosis. Therefore, it is important to keep or improve the level of patient's quality of life. The use of strontium-89 for the management of the pain from bone metastasis was approved in 2007 in Japan. A new bone-targeting radiopharmaceuticals using radium-223 is also promising, because a randomized trial showed an overall survival advantage of radium-223 in prostate patients with bone metastases. In this review, we summarize the role of targeted radionuclide therapy for castration-resistant prostate cancer, focusing on strontium-89 and radium-223.

AB - Although patients with castration-resistant prostate cancer frequently have metastases to the bone, they have a relatively favorable prognosis. Therefore, it is important to keep or improve the level of patient's quality of life. The use of strontium-89 for the management of the pain from bone metastasis was approved in 2007 in Japan. A new bone-targeting radiopharmaceuticals using radium-223 is also promising, because a randomized trial showed an overall survival advantage of radium-223 in prostate patients with bone metastases. In this review, we summarize the role of targeted radionuclide therapy for castration-resistant prostate cancer, focusing on strontium-89 and radium-223.

UR - http://www.scopus.com/inward/record.url?scp=84922243017&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84922243017&partnerID=8YFLogxK

M3 - Review article

C2 - 25518355

AN - SCOPUS:84922243017

VL - 72

SP - 2181

EP - 2185

JO - Astrophysical Journal

JF - Astrophysical Journal

SN - 0004-637X

IS - 12

ER -